Analysts Are Upgrading Esperion Therapeutics, Inc. (NASDAQ:ESPR) After Its Latest Results [Yahoo! Finance News]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance News
Esperion Therapeutics, Inc.NASDAQ:ESPRCheck out our latest analysis for Esperion TherapeuticsGM:ESPR Past and Future Earnings May 8th 2020Taking into account the latest results, the most recent consensus for Esperion Therapeutics from eleven analysts is for revenues of US$238.0m in 2020 which, if met, would be a huge 4874% increase on its sales over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 42% to US$5.55. Before this latest report, the consensus had been expecting revenues of US$199.3m and US$7.06 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.Despite these upgrades,the analysts have not made any major changes to their price target of US$80.69, implying that their latest estimates don't have a long term impact on what they think the stock is wort
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 [Yahoo! Finance]Yahoo! Finance
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- ESPR's page on the SEC website